Extractables and Leachables: An Overview of Emerging Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Extractables and Leachables: An Overview of Emerging Challenges
Extractables and leachables are a growing concern for pharmaceutical manufacturers and regulatory bodies.


Pharmaceutical Technology
Volume 32, Issue 8

Extractable and leachable studies

Extractable and leachable studies are designed to identify chemicals released or migrated from product or packaging components, such as rubber, plastic, and glass under various conditions of normal use. Extractables and leachables maybe composed of both organic substances (packaging raw materials, additives, stabilizers, accelerants, breakdown and reaction products) and inorganic substances (metal oxides, acids, etc.). These studies are performed on inhalation devices; injectables; implantable devices; ocular and nasal delivery systems; primary, secondary, and tertiary packaging components; and other products (27).

The presence of extractables is determined through artificial means. Extractable testing studies are recommended even if containers or closures meet compendial suitability tests. Extensive testing for extractables should be performed as part of the qualification of the container-closure components. Package component fabricators test for extractables from their materials as part of their own development and qualification operations. Testing under stressed conditions should demonstrate that the extractable profile is within acceptable limits for the specific dosage form and that levels observed will not be approached or exceeded during the shelf life of the drug product (5). More importantly, leachables tests are carried out at the point of use on the actual drug product. The goal of such testing is to determine that package materials are generally safe, compatible with a given dosage form, and present an acceptable risk of contamination for particular products (16). Various phases of study include (10, 11):

  • Extractable characterization (or controlled extraction study)
  • Extractable method optimization
  • Extractable method validation
  • Routine extractable testing
  • Leachable method development
  • Leachable method validation
  • Leachable testing (stability testing).

Study design

Studies are normally conducted in phases that maybe separated by long periods of time, during which, analysis, data reduction, and risk assessment are performed (10).

"Extractable characterization is the first and probably the most critical one because all other decisions and testing are based upon it. This process starts with gathering of information and continues with the profiling and characterizing the extractables. In general, preparation requires both nonpolar and polar solvents. The instrumentation employed includes high-performance liquid chromatography-photo-diode array detection-mass spectrometry (HPLC-PDA-MS) for organics analysis; gas chromatography-mass spectrometry (GC-MS) for organics analysis; inductively coupled plasma-optical emission spectroscopy or mass spectrometry (ICP-OES or ICP-MS) for metals analysis; and sometimes ion chromatography (IC) for inorganics and ion analysis. These techniques are complementary and provide a wealth of information needed to profile the extractables and leachables that may come from the packaging component(s)" (11).

"Mass spectrometry is used because it is a powerful tool that elucidates structure. Once the extraction profile is established, it is crucial that the toxicologists review the data, perform risk assessment, and propose maximum levels based on the total daily intake defined by the product dosing. After extractables have been characterized and qualified, the analytical methods are optimized and validated for the compounds of concern. Then, these methods are used for analysis of the components" (10).

Typically, several batches of components are tested, and suitable specifications are proposed for controlling consistency in the quality of these materials. Once appropriate components are chosen, analytical methods for leachables in the drug product are developed and validated. Samples of the drug products, which have been in contact with the components for an extended length of time, are tested. In case such samples are not available, the drug product and component are stressed under appropriate conditions to generate the leachables. The leachables maybe the same compounds as those identified during extractable studies or their chemical identity maybe different from the extractables because of drug product interaction. All major compounds and target compounds that do not have origins in the drug substance or excipients are identified and quantified. These goals can be accomplished by making a formulation in an inert glass container to exclude the leachables originating from the components (10, 11).

In spite of numerous problems due to leaching, there is also a silver lining. Leaching is being utilized for active packaging for numerous applications such as antioxidant release from waxed paper packs for breakfast cereals or for release of antimicrobial agents from wrapping films for preservation of food items (34).

Conclusion

Extractables and leachables are increasingly becoming a cause of major concern for both pharmaceutical industry and regulatory bodies. The presence of extractables and leachables in the drug product can adversely affect both safety and efficacy. Therefore, extractables and leachables issues should be investigated and resolved in the early stages of the drug development process. It has never been more crucial than it is currently, as FDA is seeking more and more information about each and every packaging component as well as its potential to interact with the drug. A complete characterization is also necessary because extractables and leachables may have adverse impact on product quality by affecting toxicity or interfering with the desirable characteristics of the formulation by reducing the potency of the drug, changing the solubility of the drug in the formulation, or causing other undesirable effects. A systematic and comprehensive approach is the need of the hour for identifying, quantifying and minimizing impurities emanating from extractables and leachables.

Poonam Kushwaha is a lecturer of pharmacy at Integral University, Lucknow, INDIA, and A. K. Madan* is dean of Pharmaceutical Sciences at M. D. University, Rohtak-124001, India, +91-9896346211,

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here